论文部分内容阅读
作者选择18～55岁、无生殖器疤疹史的未孕女性作为试验对象,其中18人单纯疱疹病毒(HSV)血清阴性,20人HSV-1血清阳性。分别在0、28和180天肌注含佐剂的重组HSV-2糖蛋白gB2和gD2疫苗各30μg,其中14名HSV血清阴性和16名HSV-1血清阳性者在1年后又注射第4剂疫苗。在0、28、42、90、180、194、270和360天以及第4剂后14天取宫颈分泌物,分别与经电泳的重组gB2或gD2抗原带反应,用增强的化学发光蛋白印迹法（ECL-WB）检测lgG和IgA,并用免疫印迹试验测定抗体滴度。
The authors selected 18-55-year-old, non-genital herpes history of non-pregnant women as the test object, of which 18 were herpes simplex virus (HSV) seropositive, 20 HSV-1 seropositive. Thirty μg each of the adjuvanted recombinant HSV-2 glycoprotein gB2 and gD2 vaccines was administered intramuscularly on days 0, 28 and 180, with 14 HSV seronegative and 16 HSV-1 seropositive individuals injected 4 more years later Vaccine. Cervical secretions were taken at 0, 28, 42, 90, 180, 194, 270 and 360 days, and 14 days after the 4th dose, respectively, and reacted with the band of the recombinant gB2 or gD2 antigen by electrophoresis, respectively, with enhanced chemiluminescence Western blot (ECL-WB) for lgG and IgA, and antibody titers were determined by Western blotting.